On this page

Study design

Researchers analyzed de novo Parkinson’s disease participants in the PPMI cohort who tested positive on an alpha-synuclein seed amplification assay. They classified Alzheimer’s co-pathology using cerebrospinal-fluid amyloid-beta and phosphorylated-tau measures, then compared cognition and motor outcomes over follow-up.

What the study found

Among 449 participants, 42 (9.3%) met the study’s Alzheimer’s biomarker definition. Their starting cognitive and motor scores were similar to the comparison group, but follow-up showed greater cognitive decline, more mild cognitive impairment at five years, and worse motor outcomes at eight years.

Limits and interpretation

This is an observational subgroup analysis, and biomarker cutoffs and the selected PPMI population affect who is classified. The findings do not show that Alzheimer’s biomarkers cause faster decline or prove that routine screening changes outcomes.

This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.

Sources

Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.

← All news